Bone Therapeutics is a regenerative therapy company specializing in addressing unmet medical needs in the field of bone diseases and orthopaedics. The company is bringing a new and unique treatment paradigm in this field with novel differentiated bone-forming cells administered via a minimally invasive percutaneous approach, offering significant benefits over the current standard of care which involves heavy surgery and long recovery periods.

Today, Bone Therapeutics has 2 first-in-class products, addressing multiple indications, in clinical development:

  • PREOB®, an autologous osteoblastic cell product currently in phase III clinical trials for the treatment of osteonecrosis and non-union fractures, and in a phase I/IIa for severe osteoporosis.
  • ALLOB®, an allogeneic (“off-the-shelf”) osteoblastic cell product currently in a phase I/IIa for the treatment of delayed union.

The Company also runs preclinical research programs and develops unique product candidates.

Founded in 2006, Bone Therapeutics is headquartered in Gosselies (South of Brussels, Belgium). Bone Therapeutics’ regenerative products are manufactured to the highest GMP standards and are protected by a rich IP estate.

Contact Bone Therapeutics
+32 (0)2 529 59 90
info@bonetherapeutics.com
bonetherapeutics@consilium-comms.com
Visit Website